A Phase I Study of HW201877 in Healthy Subjects

NCT07373457

Status	RECRUITING
Phase	Phase 1
Sponsor	Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Enrollment	104 participants

Key Eligibility Criteria

Inclusion (4)

- Before enrollment in the study, each subject shall sign the informed consent form and be fully apprised of the study content, implementation procedures and potential adverse reactions.
- Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 6 months after the last dose administration.
- years to 55 years (inclusive), male and female.
- Male subjects weight e50 kg and female subjects weight e45 kg. Bodymass index (BMI) : 18-28 kg/m2 (inclusive) .

Exclusion (9)

- Smoking more than 5 cigarettes per day within 3 months prior to screening.
- Allergic diathesis (with a history of allergies to multiple drugs and foods).
- A history of drug abuse and/or alcoholism (consuming 14 units of alcohol per week; 1 unit = 285 mL of beer, 25 mL of distilled spirits, or 100 mL of wine).
- Have taken any medications that alter hepatic enzyme activity within 28 days prior to screening.
- Have consumed special diets (including pitaya, mango, lime, grapefruit, carambola, orange, grapefruit or grapefruit-containing products, etc.) or engaged in strenuous exercise within 2 weeks prior to screening, or having other factors that may affect the absorption, distribution, metabolism and excretion of the study drug.

... and 4 more (see full listing online)

Locations (1 total)

The First Hospital of Jilin University, Changchun, China